WO2002040031A1 - Preparation adhesive contenant estradiol - Google Patents
Preparation adhesive contenant estradiol Download PDFInfo
- Publication number
- WO2002040031A1 WO2002040031A1 PCT/JP2001/009915 JP0109915W WO0240031A1 WO 2002040031 A1 WO2002040031 A1 WO 2002040031A1 JP 0109915 W JP0109915 W JP 0109915W WO 0240031 A1 WO0240031 A1 WO 0240031A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patch
- estradiol
- drug
- sensitive adhesive
- liquid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Definitions
- the present invention relates to a patch containing extradiol. Background art
- the estrogen, estradiol is also disclosed in, for example, Japanese Patent Application Publication No. 3-520925 and Japanese Patent Application Publication No. 6-5303756, in which Absorption enhancers have been proposed to improve the absorption.
- Absorption enhancers have been proposed to improve the absorption.
- An object of the present invention is to provide a patch which is excellent in skin permeability of estradiol, maintains the skin permeability for a long time, and is excellent in safety and economy.
- the present inventors have conducted intensive studies to achieve such an object, and have found that a specific absorption promoter is used in a patch provided with an adhesive layer containing estradiol, an absorption accelerator, and an adhesive. As a result, it has been found that the object of the present invention is achieved, and the present invention has been completed. Disclosure of the invention
- the present invention provides a patch in which an adhesive layer containing a drug, an absorption promoter and an adhesive is provided on one surface of a flexible support,
- the drug is estradiol
- the absorption enhancer comprises at least one selected from sorbitan monolaurate and polyethylene glycol monolaurate, and at least one selected from higher fatty acid esters and hydrocarbons which are liquid at room temperature;
- the pressure-sensitive adhesive is an acrylic pressure-sensitive adhesive
- the absorption promoter used in the present invention is selected from sorbitan monolaurate and polyethylene glycol monolaurate-and one selected from higher fatty acid esters and hydrocarbons which are liquid at room temperature. It is important that this is a mixture of the above. Only when this mixture is used, it is possible to obtain a patch having excellent transdermal absorbability and long-lasting skin permeability of estradiol.
- the absorption promoter is at least one selected from sorbitan monolaurate and polyethylene glycol monolaurate, a patch having the above properties cannot be obtained. Similarly, even when only one or more selected from higher fatty acid esters and hydrocarbons which are liquid at room temperature, such patches cannot be obtained.
- At least one selected from higher fatty acid esters and hydrocarbons which are liquid at room temperature is preferably a mixture of higher fatty acid esters and hydrocarbons. This is because it is effective not only in improving and sustaining the absorption of estradiol, but also in terms of skin adhesion and economics.
- the mixing ratio is preferably 0.1: 0.9 force, and 0.8: 0.2.
- the absorption enhancer of the present invention is preferably sorbitan monolaurate from the viewpoints of improving the absorption of estradiol, continuously improving the absorption, adhesion to the skin, economy, and water resistance to bathing. It is particularly preferred that the mixture is a mixture of carboxylic acids, higher fatty acid esters, and hydrocarbons.
- Examples include isopropyl succinate, isopropyl palmitate, isostearyl palmitate, ethyl oleate, oleyl oleate, decyl oleate, getyl sebacate, and hexyl laurate.
- isopropyl myristate, isopropyl palmitate, or ethyl oleate are preferred from the viewpoints of improving the absorption of estradiol, maintaining the effect over a long period of time, and irritating the skin.
- isopropyl myristate can be mentioned as a particularly preferred one.
- hydrocarbons according to the present invention examples include liquid paraffin, squalane, squalene, gelled hydrocarbons, and petrolatum. Liquid paraffin and / or squalane are preferred from the viewpoints of improvement, sustained absorption, economy and adhesive strength.
- the content of one or more selected from sorbitan monolaurate and polyethylene glycol monolaurate in the pressure-sensitive adhesive layer is preferably 2 wt% or more and 10 wt% or less.
- the content is less than 2 wt%, it is difficult to improve the sufficient skin permeability of the drug, and when the content exceeds 1 wt%, the effect of improving the skin permeability of the drug is leveled off. Therefore, it is not preferable in terms of safety and economy.
- the content in one or more pressure-sensitive adhesive layers selected from higher fatty acid esters and hydrocarbons which are liquid at room temperature is preferably 5 wt% or more and 35 wt% or less. If the content is less than 5 wt%, it is difficult to maintain sufficient skin permeability of the drug and long-term skin permeability. On the other hand, if it exceeds 35 wt%, the effect of improving the skin permeability of the drug is improved. As the fruits peak, they are less favorable from an economic point of view. In addition, when the patch is applied to the skin and peeled off, glue residue easily forms on the skin.
- the acryl-based pressure-sensitive adhesive in the present invention contains an alkyl (meth) acrylate having 2 to 20 carbon atoms as a main component, and has an (meth) acrylate of 10% or less. ) Acrylic acid-containing (meth) alkyl acrylate copolymers are preferred.
- the alkyl (meth) acrylate having 2 to 20 carbon atoms include ethyl (meth) acrylate, butyl (meth) acrylate, and pentyl (meta).
- (meth) alkyl acrylate means an alkyl acrylate or an alkyl methacrylate.
- an acrylic adhesive may be mixed with a vinyl acetate adhesive or a silicone adhesive in an amount less than the equivalent amount of the acrylic adhesive.
- estradiol of the present invention refers to natural estrogen, synthetic estrogen, and derivatives thereof, for example, estradiol benzoate, estradiol benzoate, estradiol dipropionate, Estradiol valerate, ethynyl estradiol, and the like. Among them, estradiol is preferred.
- the content of the estradionil of the present invention in the patch is preferably 0.4 wt% or more and 2.5 wt% or less, particularly preferably 0.6 wt% or more and 2.01% or less. . If the content is less than 0.4 wt%, it is difficult to obtain a sufficient amount of the drug through the skin. On the other hand, if the content exceeds 2.5 wt%, it is uneconomical because the amount of residual drug in the patch after use increases.
- a conventionally known method can be employed as a method for incorporating a drug into the pressure-sensitive adhesive layer.
- a method for incorporating a drug into the pressure-sensitive adhesive layer a conventionally known method can be employed.
- a method in which a drug solution is preliminarily mixed with a solution-type pressure-sensitive adhesive to form a drug-containing pressure-sensitive adhesive layer, or a pressure-sensitive adhesive layer that does not contain a drug or does not sufficiently contain a drug is impregnated, inverted, or This is a method in which the drug is contained in a sufficient amount for transdermal absorption by wearing or spraying.
- Crosslinking may be performed in the pressure-sensitive adhesive layer of the present invention for the purpose of improving the cohesive strength of the pressure-sensitive adhesive layer.
- a cross-linking method include cross-linking by ultraviolet rays or ultraviolet rays, or the use of a polymer such as a caustic anhydride, a polyisocyanate compound, an organic metal salt, a metal chelate compound, or a polymer capable of forming a polyion complex.
- a method of adding a crosslinking agent to perform crosslinking can be used.
- stabilizers such as magnesium stearate, zinc stearate, and citric anhydride; for example, ascorbic acid, toco acetate Antioxidants such as ferol and vitamin E; fragrances such as menthol, potato fulness, oil, lemon oil; preservatives such as dibutylhydroxytoluene and isobutyl paraoxybenzoate;
- pH adjusters such as sodium citrate, sodium dihydrogen citrate, sodium hydrogen phosphite, sodium hydrogen phosphite and the like can be mentioned. These can be used alone or in combination of one or more.
- the support used in the present invention is not particularly limited as long as it can adhere an adhesive layer and has a self-shape retention property.
- the material and shape are not particularly limited. Absent.
- polymer films such as polyester, polyolefin, polyvinyl chloride, polyurethane, and cellulose ester; fibers such as polyester, polyolefin, polyurethane, cellulose ester, and polyamide.
- the thickness of the support is not particularly limited, but is preferably 50 to 100 m from the viewpoint of handleability.
- the thickness of the pressure-sensitive adhesive layer in the present invention is not particularly limited, but is preferably from 10 to 300 m, and particularly preferably from 40 to 200 m.
- sorbitan monolaurate and polyethylene are used as absorption accelerators.
- Polyacrylic acid alkyl ester copolymer solution consisting of 90% 2-ethylhexyl acrylate, 7% methyl methacrylate, and 3% acrylic acid as an acrylic adhesive (Solid content: 15%) 24.3 parts: 1.2 parts of a 5% solution of estradiol in acetate, 0.2 part: sorbitan monolaurate: 0.25 parts, isopropyl myristate: 1.0 Parts, 0.05 parts of polyvinylpyrrolidone, 19 parts of ethyl acetate and 13 parts of ethanol were added as a crosslinking agent.
- a patch was obtained in the same manner as in Example 1 except that the composition shown in Table 1 was changed.
- Example 1 Example 2 Example 3 Example 4 Example 5 Example 6 Example 7 Example 8 Comparative Example 1 Comparative Example 2 Estradiol 1.2 1.2 0.8 1.2 1.2 1.8 1.2 1.2 1.2 1.2 Acrylic adhesive 72.8 85.3 74.1 73.7 73.7 82.7 72.8 78.3 72.8 92.8 Sorbitan monolaurate 5 2.5 5 5 5 5 5 5 Poly-polykishetylene monolaurate 5 5
- Crosslinker 1 1 0.1 0.1 0.1 0.5 1 0.5 1 1 1 Blood drug concentration: 7 hours after application 4168 3802 3959 4103 3756 6432 3929 4005 2183 1343 (pg / ml): 24 hours after application 1938 1462 2505 2342 1625 2362 1618 2156 960 812
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-7006318A KR100533493B1 (ko) | 2000-11-17 | 2001-11-13 | 에스트라디올 함유 부착제 |
JP2002542404A JP3935839B2 (ja) | 2000-11-17 | 2001-11-13 | エストラジオール含有貼付剤 |
AU2002212763A AU2002212763A1 (en) | 2000-11-17 | 2001-11-13 | Adhesive preparation containing estradiol |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000350657 | 2000-11-17 | ||
JP2000-350657 | 2000-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002040031A1 true WO2002040031A1 (fr) | 2002-05-23 |
Family
ID=18823846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/009915 WO2002040031A1 (fr) | 2000-11-17 | 2001-11-13 | Preparation adhesive contenant estradiol |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP3935839B2 (ko) |
KR (1) | KR100533493B1 (ko) |
CN (1) | CN1198621C (ko) |
AU (1) | AU2002212763A1 (ko) |
WO (1) | WO2002040031A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006515617A (ja) * | 2003-01-03 | 2006-06-01 | ディーピーシー プロダクツ, インコーポレイテッド | ギルソナイト由来薬学的送達組成物および方法 |
JP2019210440A (ja) * | 2018-06-08 | 2019-12-12 | 株式会社日本触媒 | 粘着剤組成物及びその利用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0344327A (ja) * | 1989-07-10 | 1991-02-26 | Sekisui Chem Co Ltd | 経皮吸収製剤 |
JPH0344326A (ja) * | 1989-07-10 | 1991-02-26 | Sekisui Chem Co Ltd | 経皮吸収製剤 |
WO1996003131A1 (fr) * | 1994-07-22 | 1996-02-08 | Sekisui Kagaku Kogyo Kabushiki Kaisha | Preparation se pretant a une absorption percutanee |
JPH09100227A (ja) * | 1989-09-08 | 1997-04-15 | Cygnus Inc | 経皮ドラッグデリバリーのための固体マトリックスシステム |
JPH09315957A (ja) * | 1996-05-28 | 1997-12-09 | Hisamitsu Pharmaceut Co Inc | 経皮治療用装置 |
WO2000064418A2 (de) * | 1999-04-22 | 2000-11-02 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches system mit neutralisierten acrylhaftklebern |
-
2001
- 2001-11-13 KR KR10-2003-7006318A patent/KR100533493B1/ko not_active IP Right Cessation
- 2001-11-13 AU AU2002212763A patent/AU2002212763A1/en not_active Abandoned
- 2001-11-13 WO PCT/JP2001/009915 patent/WO2002040031A1/ja active IP Right Grant
- 2001-11-13 CN CNB018190901A patent/CN1198621C/zh not_active Expired - Fee Related
- 2001-11-13 JP JP2002542404A patent/JP3935839B2/ja not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0344327A (ja) * | 1989-07-10 | 1991-02-26 | Sekisui Chem Co Ltd | 経皮吸収製剤 |
JPH0344326A (ja) * | 1989-07-10 | 1991-02-26 | Sekisui Chem Co Ltd | 経皮吸収製剤 |
JPH09100227A (ja) * | 1989-09-08 | 1997-04-15 | Cygnus Inc | 経皮ドラッグデリバリーのための固体マトリックスシステム |
WO1996003131A1 (fr) * | 1994-07-22 | 1996-02-08 | Sekisui Kagaku Kogyo Kabushiki Kaisha | Preparation se pretant a une absorption percutanee |
JPH09315957A (ja) * | 1996-05-28 | 1997-12-09 | Hisamitsu Pharmaceut Co Inc | 経皮治療用装置 |
WO2000064418A2 (de) * | 1999-04-22 | 2000-11-02 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches system mit neutralisierten acrylhaftklebern |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006515617A (ja) * | 2003-01-03 | 2006-06-01 | ディーピーシー プロダクツ, インコーポレイテッド | ギルソナイト由来薬学的送達組成物および方法 |
JP2019210440A (ja) * | 2018-06-08 | 2019-12-12 | 株式会社日本触媒 | 粘着剤組成物及びその利用 |
JP7112256B2 (ja) | 2018-06-08 | 2022-08-03 | 株式会社日本触媒 | 粘着剤組成物及びその利用 |
Also Published As
Publication number | Publication date |
---|---|
CN1198621C (zh) | 2005-04-27 |
JPWO2002040031A1 (ja) | 2004-03-18 |
AU2002212763A1 (en) | 2002-05-27 |
KR100533493B1 (ko) | 2005-12-06 |
KR20040011430A (ko) | 2004-02-05 |
CN1474695A (zh) | 2004-02-11 |
JP3935839B2 (ja) | 2007-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4660858B2 (ja) | 経皮吸収型製剤 | |
JP5016309B2 (ja) | 医療用テープ剤 | |
GB2273044A (en) | Medicinal patches for percutaneous administration | |
US20060193900A1 (en) | Pressure sensitive adhesive and patch | |
WO2001062254A1 (fr) | Pieces contenant de la buprenorphine chlorhydrate | |
EP0450986B1 (en) | A percutaneous-administration-type pharmaceutical preparation of nitroglycerin | |
JPH06205839A (ja) | 経皮投与型薬物用貼付剤 | |
WO2003103641A1 (ja) | 貼付剤 | |
JP2017511174A (ja) | 改善された適合性(compatibility)および長い接着期間を有するオーバーパッチ(over−patch)、ならびに前記オーバーパッチを製造するための方法 | |
JP5684441B2 (ja) | インドメタシン含有貼付剤 | |
JP2004504409A (ja) | ポリアクリレートおよびポリアミン塩の2相接着剤マトリックスを含有する医療用接触接着性組成物 | |
WO2002040031A1 (fr) | Preparation adhesive contenant estradiol | |
JP4988080B2 (ja) | 経皮吸収型製剤 | |
JPH08143458A (ja) | 経皮吸収貼付剤 | |
WO2004066985A1 (ja) | 薄型水性貼付剤 | |
JP3046330B2 (ja) | 貼付製剤 | |
JP5226230B2 (ja) | 貼付剤用粘着剤組成物及びその用途 | |
JP3406188B2 (ja) | 貼付剤 | |
JP2005529150A (ja) | 気管支拡張薬を有するマトリックスタイプパッチ | |
JP3226395B2 (ja) | 経皮吸収貼付剤 | |
JP4869583B2 (ja) | 角質剥離が少ない貼付剤 | |
WO2004014395A1 (ja) | 女性ホルモン含有貼付剤 | |
JP2008101028A (ja) | 経皮吸収型製剤 | |
WO2021106782A1 (ja) | ロピニロール含有貼付剤の粘着剤層保持力向上方法、及びロピニロール含有保持力改善貼付剤 | |
CA2336704A1 (en) | Composition containing glycerol trinitrate, method for producing said composition and use of the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002542404 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037006318 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018190901 Country of ref document: CN |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 1020037006318 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020037006318 Country of ref document: KR |